Development and characteristics of a human cell assay for screening agents for melanoma prevention

Melanoma Research

Volumn 17, Issue 1, 2007, Pages 42-50

  Elmore, Eugene ^a,b   Jain, Aarti ^a   Siddiqui, Shazia ^a   Tohidian, Nilou ^a,b   Meyskens, Frank L ^a,b   Steele, Vernon E ^c   Redpath, John L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer prevention; E cadherin N cadherin; Melanoma; Screening

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; DIPHENHYDRAMINE; EFLORNITHINE; FENRETINIDE; HLA DR ANTIGEN; LIPOCORTIN 5; MANNITOL; NERVE CELL ADHESION MOLECULE; NIMESULIDE; NORDIHYDROGUAIARETIC ACID; POLYPHENON E; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CELL ASSAY; CELL CLONING; CELL SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GROWTH CURVE; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; SCREENING; ULTRAVIOLET B RADIATION;

ANNEXIN A5; CADHERINS; CELL LINE; CELL LINE, TUMOR; FORESKIN; HUMANS; INFANT, NEWBORN; MALE; MASS SCREENING; MELANOCYTES; MELANOMA; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 33846458674     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3280142f96     Document Type: Article

References (28)

1. Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression. Mol Carcinog 1998; 23:132-143.
2. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. New Engl J Med 1999; 340:1341-1348.
3. Rigel DS. Epidemiology and prognostic factors in malignant melanoma. Ann Plast Surg 1992; 28:7-8.
4. Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979; 40:774-781.
5. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. In: Clark WH, Goldman L, Mastrangelo MJ, editors. Human malignant melanoma. New York: Grune and Stratton; 1979. pp. 139-166.
6. Hussein MR, Haemel AK, Sudilovsky O, Wood GS. Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation. J Clin Pathol 2005; 58:389-396.
7. Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma development. Melanoma Res 2000; 10:303-312.
8. Perlis C, Herlyn M. Recent advances in melanoma biology. Oncologist 2004; 9:182-187.
9. Hsu M-Y, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002; 70:522-536.
10. Li G, Satyamoorthy K, Herlyn M. N-Cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001; 61:3819-3825.
11. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J Exp Med 1984; 160:255-269.
12. Niles RM, McFarland M, Weimer MB, Redkar A, Fu Y-M, Meadows GG. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 2003; 190:157-163.
13. Eisinger M, Marko O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 1982; 79:2018-2022.
14. Halaban R, Alfano FD. Selective elimination of fibroblasts from cultures of normal human melanocytes. In vitro 1984; 20:447-450.
15. Jambrosic J, Mancianti ML, Ricciardi R, Sela B, Koprowski H, Herlyn M. Transformation of normal human melanocytes and non-malignant cells by adenovirus 12-SV40 hybrid virus. Int J Cancer 1989; 44:1117-1123.
16. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, et al. Melanoma cell lines from different stages of progression and their biological and molecular analysis. Melanoma Res 1997; 7 (Suppl 2):S35-S42.
17. Thomson SP, Meyskens FL. Method for measurement of self-renewal capacity of clonogenic cells from biopsies of metastatic human malignant melanoma. Cancer Res 1982; 42:4606-4613.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983; 65:55-63.
19. Riss TL, Moravec RA. Comparison of MTT, XTT and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 1992; 3 (Suppl 3):184a.
20. Meier F, Satyamoorthy K, Nesbit M, Hsu M-Y, Schitek B, Garbe C, et al. Molecular events in melanoma development and progression. Front Biosci 1998; 3:1005-1010.
21. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996; 1:188-194.
22. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, et al. Dose de-escalation chemoprevention trial of difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994; 86:1122-1130.
23. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11:2036-2042.
24. Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, et al. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol Biomark Prev 2003; 12:34-41.
25. Garaventa A, Luksch R, Piccolo MSL, Cavadini E, Montaldo PG, Pissitola MR, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003; 9:2031-2039.
26. Barrientos-Astigarraga RE, Vannuchi YB, Sucupira M, Moreno RA, Muscara MN, De Nucci G. Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies. J Mass Spectrom 2001; 36:1281-1286.
27. Chow H-HS, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomark Prev 2001; 10:53-58.
28. Weber C, Dumont E. Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men. J Clin Pharmacol 1997; 37:566-574.